Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Biogen Explodes Higher After Potential Mega Blockbuster Alzheimer's Drug Succeeds

Biogen stock catapulted Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test.

Investors Business Daily

Alzheimer's drug shows promise in early results of study

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study

The Independent UK

Success of experimental Alzheimer’s drug hailed as ‘historic moment’

Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Is iPhone Demand Really Slowing Down?, Lyft Freezes Hiring, Biogen's New Drug Slows Alzheimer's Progression: Top Financial Media Stories Wednesday, Sept. 28

Bloomberg

Benzinga

Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket

Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.

Benzinga

Nasdaq Futures Slip But S&P 500, Dow Futures Hold Up Ahead Of Market Open — Apple, Biogen Stocks In Focus

U.S. stocks could struggle for direction on Wednesday after the market struggled en route to a mixed close in the previous session. Volatility could be the order of the day as another batch of Fed speeches are in the pipeline.

Benzinga

Biogen Stock Soars On Promising Data From Late-Stage Alzheimer’s Drug Trial

“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease," said Biogen CEO Michel Vounatsos.

The Street

Read news from The Economist, FT, and more,
with one subscription

World's first EVER drug shown to work against Alzheimer's developed by scientists

Scientists say the development of the only drug to work against Alzheimer’s is a 'historic moment' - with regulators expected to approve the groundbreaking drug by the New Year

Daily Mirror

Stocks Resume Slump, Apple, Biogen, Elon Musk And Hurricane Ian - Five Things To Know

Stock futures resume slump on rate hike, recession concerns; Apple shares slide on report of waning iPhone demand; Biogen shares soar after positive results from Alzheimer's trial; Elon musk seeks to overturn sec rule on Twitter vetting and Hurricane Ian to slam Florida coast as category 4 storm.

The Street

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

Benzinga

Dow Jones Futures Volatile On Bank Of England Reversal; Apple Falls On iPhone Report, Biogen Soars On Alzheimer's Drug

Apple is curbing iPhone production. The 10-year yield hit 4%, until the Bank of England stepped in. A Biogen Alzheimer's drug shows promise.

Investors Business Daily

Alzheimer’s progression slowed by drug in major trial

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

Tribune News Service

Biogen Makes Big Payout to Settle DOJ Whistleblower Case

The whistleblower provision has been around for a long time but it still has plenty of bite.

The Street

Check Out What Whales Are Doing With BIIB

A whale with a lot of money to spend has taken a noticeably bullish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 19 strange trades.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Biogen pays $900M to settle doctor kickback allegations

Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors in the form of speakers and consulting fees to persuade them to prescribe its multiple sclerosis drugs

The Street

Biotech Valuations Remain In a Slump

Biotech stocks remain undervalued, but investors could start building a position.

Investors Business Daily

IBD Stock Of The Day: Could 'The Biggest Drug Ever' Drive Eli Lilly Stock Even Higher?

Eli Lilly is the IBD Stock Of The Day as investors watch the company's obesity and Alzheimer's drugs, which could help shares skyrocket.

Daily Mirror

Rugby legends hail Motor Neurone Disease breakthrough that 'will bring hope to thousands'

A breakthrough in MND treatment has been described as 'remarkable’ as rugby greats Doddie Weir and Rob Burrow - both diagnosed with the condition - say there is hope for the future

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The 'Transformative' Eli Lilly Drug That Could Top $25 Billion In Annual Sales

Eli Lilly's blockbuster potential diabetes drug Mounjaro is "de-risked and transformative," an analyst said Thursday as he updated LLY stock.

Evening Standard

Tofersen: ‘Truly remarkable’ drug slows down motor neurone disease, researchers find

Researchers say improvements reported with tofersen was ‘moment of hope’ for disease

The Independent UK

‘Truly remarkable’ new drug slows motor neuron disease

Extended use of tofersen may help stabilise muscle strength and control, researchers say

The Guardian - UK

Experimental drug shows signs of slowing motor neurone disease

Biogen drug Tofersen showed promising results when taken for six months beyond previous trial

The Independent UK

‘Promising’ new drug shown to slow motor neurone disease progression

Extended use of tofersen may help stabilise muscle strength and control, researchers say.

Benzinga

Looking At Biogen's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Investors Business Daily

Something Unusual Is Happening Right Now With Biotech Stocks

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.